TwinBeech Capital’s Allogene Therapeutics ALLO Stock Holding History

TwinBeech Capital’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-326,253	Closed	-$1.61M	–	575
2023 Q1	$1.61M	Sell	326,253 -29,791	-8%	-$191K	0.03%	396
2022 Q4	$2.24M	Buy	356,044 +160,609	+82%	+$1.49M	0.04%	416
2022 Q3	$2.11M	Buy	+195,435	New	+$2.66M	0.06%	330
2022 Q1	–	Sell	-40,395	Closed	-$603K	–	483
2021 Q4	$603K	Buy	+40,395	New	+$713K	0.03%	404

Other funds holding ALLO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TwinBeech Capital's ALLO Position: Q2 2023 in Review

TwinBeech Capital sold out of Allogene Therapeutics (ALLO) in Q2 2023, closing a stake of 326,253 shares — an estimated $1.61M sold.

TwinBeech Capital first reported a position in ALLO in Q4 2021 and held it in 4 quarters. The position peaked at $2.24M in Q4 2022. 171 funds tracked by Wall St. Rank hold ALLO as of Q2 2023.

TwinBeech Capital reported no remaining Allogene Therapeutics position as of Q2 2023 after selling out during the quarter.
TwinBeech Capital sold 326,253 Allogene Therapeutics shares in Q2 2023, an estimated $1.61M.
TwinBeech Capital first reported a position in Allogene Therapeutics in Q4 2021 and held it in 4 quarters.
TwinBeech Capital's Allogene Therapeutics position peaked at $2.24M in Q4 2022.
171 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2023.

Based on TwinBeech Capital's 13F filing for Q2 2023, filed 14 Aug 2023.